Iacobelli S, Scambia G, Atlante G, Landoni F, Sismondi P, Vecchio F M
Eur J Cancer Clin Oncol. 1986 Jan;22(1):105-10. doi: 10.1016/0277-5379(86)90349-4.
Estrogen receptor (ER), progesterone receptor (PR) and creatine kinase (CK) were measured in cancerous tissue from 29 post-menopausal patients with endometrial carcinoma under basal conditions and after a short course of tamoxifen treatment. ER and PR were detected in nearly all tumors. CK was detected in all of the tumors examined. After tamoxifen, PR and CK increased simultaneously in 26% of cases, while they were either enhanced, decreased or unmodified in the remainder. No correlation could be found between increase of PR and tumor differentiation. CK, however, was enhanced only in the more differentiated cancers. These results indicate that only a percentage of endometrial cancers are responsive to tamoxifen. It is hypothesized that patients bearing these tumors are those likely to benefit from endocrine therapy.
在基础条件下以及短期服用他莫昔芬治疗后，对29例绝经后子宫内膜癌患者的癌组织进行了雌激素受体（ER）、孕激素受体（PR）和肌酸激酶（CK）检测。几乎在所有肿瘤中均检测到ER和PR。在所有检测的肿瘤中均检测到CK。服用他莫昔芬后，26%的病例中PR和CK同时升高，而其余病例中PR和CK要么升高、要么降低、要么无变化。PR升高与肿瘤分化之间未发现相关性。然而，CK仅在分化程度较高的癌症中升高。这些结果表明，只有一定比例的子宫内膜癌对他莫昔芬有反应。据推测，患有这些肿瘤的患者可能会从内分泌治疗中获益。
